European Adrenal Insufficiency Registry (EU-AIR): A comparative observational study of glucocorticoid replacement therapy

BMC Endocrine Disorders

Volumn 14, Issue , 2014, Pages

  Ekman, Bertil ^a   Fitts, David ^b   Marelli, Claudio ^c   Murray, Robert D ^d   Quinkler, Marcus ^e   Zelissen, Pierre M J ^f  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ViroPharma Incorporated   (United States)

^c ViroPharma Chatsworth House   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE; PREDNISOLONE; GLUCOCORTICOID;

ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MODIFIED DRUG RELEASE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIMARY ADRENAL INSUFFICIENCY; SECONDARY ADRENAL INSUFFICIENCY; ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; AGED; CHILD; CIRCADIAN RHYTHM; COMPARATIVE STUDY; EUROPE; FOLLOW UP; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADRENAL INSUFFICIENCY; ADULT; AGED; AGED, 80 AND OVER; CHILD; CIRCADIAN RHYTHM; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; MORBIDITY; PROGNOSIS; YOUNG ADULT;

EID: 84902135582     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-14-40     Document Type: Article

References (33)

1. Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 2001, 163:1520-1523. 10.1164/ajrccm.163.7.2012022, 11401866.
2. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003, 361:1881-1893. 10.1016/S0140-6736(03)13492-7, 12788587.
3. van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol 2004, 151(Suppl 3):U71-U75.
4. Healio Endocrinology Adrenal insufficiency requires improved management, alternative therapy. Endocrine today October 2012: http://www.healio.com/endocrinology/adrenal/news/print/endocrine-today/%7B65f1492c-8956-45df-9b31-c0c31ac46a82%7D/adrenal-insufficiency-requires-improved-management-alternativetherapy, Healio Endocrinology.
5. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord 2012, 12:8. 10.1186/1472-6823-12-8, 3403959, 22695167.
6. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engstrom BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, Skrtic S. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012, 97:473-481. 10.1210/jc.2011-1926, 22112807.
7. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006, 91:4849-4853. 10.1210/jc.2006-0076, 16968806.
8. Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, Cox C, Kong F, Fradkin JE. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004, 144:430-436. 10.1016/j.jpeds.2003.12.036, 15069388.
9. Bensing S, Brandt L, Tabaroj F, Sjoberg O, Nilsson B, Ekbom A, Blomqvist P, Kampe O. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 2008, 69:697-704. 10.1111/j.1365-2265.2008.03340.x, 18727712.
10. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996, 81:1169-1172.
11. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46:75-81. 10.1046/j.1365-2265.1997.d01-1749.x, 9059561.
12. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336:285-288. 10.1016/0140-6736(90)91812-O, 1973979.
13. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001, 357:425-431. 10.1016/S0140-6736(00)04006-X, 11273062.
14. Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency?. Clin Endocrinol (Oxf) 2012, 76:21-25. 10.1111/j.1365-2265.2011.04103.x, 21585418.
15. Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, Ventz M, Quinkler M, Allolio B. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol 2010, 162:597-602. 10.1530/EJE-09-0884, 19955259.
16. Burman P, Mattsson AF, Johannsson G, Hoybye C, Holmer H, Dahlqvist P, Berinder K, Engstrom BE, Ekman E, Erfurth EM, Svensson J, Wahlberg J, Karlsson FA. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab 2013, 98(4):1466-75. 10.1210/jc.2012-4059, 23457412.
17. Lovas K, Gjesdal CG, Christensen M, Wolff AB, Almas B, Svartberg J, Fougner KJ, Syversen U, Bollerslev J, Falch JA, Hunt PJ, Chatterjee VK, Husebye ES. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009, 160:993-1002. 10.1530/EJE-08-0880, 19282465.
18. Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012, 97:85-92. 10.1210/jc.2011-2036, 21994966.
19. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006, 91:3954-3961. 10.1210/jc.2006-0524, 16895963.
20. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:764-770. 10.7326/0003-4819-141-10-200411160-00007, 15545676.
21. Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B, Quinkler M. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 2008, 159:811-817. 10.1530/EJE-08-0578, 18819943.
22. Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, Quinkler M. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010, 72:297-304. 10.1111/j.1365-2265.2009.03596.x, 19508599.
23. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W, Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007, 92:3912-3922. 10.1210/jc.2007-0685, 17684047.
24. ViroPharma SPRL. Plenadren 5 mg Modified-Release Tablets: Summary of Product Characteristics 2011,
25. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 2009, 161:119-130. 10.1530/EJE-09-0170, 19383806.
26. Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm 2006, 2:143-151. 10.1016/j.sapharm.2005.12.001, 17138506.
27. Castillo RC, Scharfstein DO, MacKenzie EJ. Observational studies in the era of randomized trials: finding the balance. J Bone Joint Surg Am 2012, 94(Suppl 1):112-117.
28. Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009, 160:719-729. 10.1530/EJE-08-0874, 19168600.
29. Growth Hormone Therapy in Pediatrics - 20 Years of KIGS 2007, Karger.
30. Schneider HJ, Klotsche J, Wittchen HU, Stalla GK, Schopohl J, Kann PH, Kreitschmann-Andermahr I, Wallaschofski H. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 2011, 75:825-830. 10.1111/j.1365-2265.2011.04137.x, 21658091.
31. Clarke JT, Giugliani R, Sunder-Plassmann G, Elliott PM, Pintos-Morell G, Hernberg-Stahl E, Malmenas M, Beck M. Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS). Value Health 2011, 14:862-866. 10.1016/j.jval.2011.05.002, 21914507.
32. Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M, Kroiss M, Jurowich C, Langer P, Oelkers W, Spahn M, Willenberg HS, Mäder U, Allolio B, Fassnacht M. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int 2010, 107:885-891. 3021904, 21246024.
33. Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, Rump LC, Seufert J, Quinkler M, Bidlingmaier M, Beuschlein F, Endres S, Reincke M. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 2009, 106:305-311. 2689591, 19547646.